PDUFA III Or Hatch/Waxman II?: Payors Urge Fix For Generic “Loopholes”
This article was originally published in The Tan Sheet
Executive Summary
Supporters of the generic industry's Hatch/Waxman agenda are eyeing the Prescription Drug User Fee Act reauthorization as a potential vehicle for reform measures
You may also be interested in...
PDUFA III Deal Includes Risk Management Fees In “Peri-Approval” Phase
The FDA/industry PDUFA III agreement includes funding to expand FDA's Office of Drug Safety by 100 full-time equivalent staff positions over five years
FDA Budget Includes 61% PDUFA Increase; Agency Wants Proposal By May
FDA aims to reach an agreement with industry on the framework for reauthorization of the Prescription Drug User Fee Act by May, Acting Senior Associate Commissioner for Management & Systems Jeff Weber said Feb. 5 during a press briefing on the FDA budget
National uniformity compromise obtainable to bring FDA reform bill to floor -- Sen. Kennedy.
NATIONAL UNIFORMITY "COMPROMISES CAN BE REACHED," SEN. KENNEDY told Senate Majority Leader Trent Lott (R-Miss.) in floor remarks made July 31 prior to the August congressional recess. Sen. Edward Kennedy (D-Mass.), the Labor & Human Resources Committee ranking minority member, suggested that "acceptable compromises can be reached" in negotiations on federal pre-emption of states' authority to regulate OTCs and cosmetics and on device-related provisions in Sen. James Jeffords' (R-Vt.) FDA reform bill (S 830).